According to statistics, the prevalence of atypical hemolytic uremic syndrome (aHUS) is about seven in one million. The majority of aHUS have complement-related factor gene mutations, and the etiology of about 6%Read More…
With the global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still ongoing, the prevention and treatment of COVID-19 has become a research focus inRead More…
On February 4, 2022, Sanofi announced that its complement C1s antibody Sutimlimab was approved by the FDA for the treatment of cold agglutinin disease (CAD) under the trade name Enjaymo. Sutimlimab isRead More…